Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBRX19
- Development stage
- Preclinical
- Lead developer
- Stramsen Biotech
- Administration
- Oral
01
Overview
SBRX19 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of influenza (flu), fever, asthma, and cough. It is part of the company's SBRX series of botanical therapeutics, which are derived from a proprietary database of over 8,000 medicinal plants. The drug is designed to function as both a herbal medicine and a pharmaceutical therapeutic, targeting viral symptoms and respiratory distress. SBRX19 is currently in the early stages of clinical development, with the developer reporting that similar formulations in their pipeline are already in use in certain international markets.
Beyond the preview
Go deeper on SBRX19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBRX19.